Serological Evaluation of Soluble CD44 in Renal Cancer
In this study, we examined the feasibility of using elevated serum CD44 concentration as an indicator in renal cancer. We performed enzyme‐linked immunosorbent assays using 63 sera obtained from 47 patients with renal cancer and 16 healthy controls and evaluated the clinico‐pathological parameters....
Gespeichert in:
| Veröffentlicht in: | Cancer science 1996-11, Vol.87 (11), p.1191-1194 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1194 |
|---|---|
| container_issue | 11 |
| container_start_page | 1191 |
| container_title | Cancer science |
| container_volume | 87 |
| creator | Kan, Masaharu Kanayama, Hiro‐omi Naruo, Seiichi Tsuji, Masahito Kojima, Keiji Kurokawa, Yasushi Kagawa, Susumu |
| description | In this study, we examined the feasibility of using elevated serum CD44 concentration as an indicator in renal cancer. We performed enzyme‐linked immunosorbent assays using 63 sera obtained from 47 patients with renal cancer and 16 healthy controls and evaluated the clinico‐pathological parameters. The concentration of soluble CD44 standard (sCD44std), indicating the concentration of all circulating CD44 isoforms, was significantly higher in renal cancer patients than in normal individuals (745±170 ng/ml vs. 563±159 ng/ml, P=0.001). The concentration of soluble CD44 splice isoforms sharing exon v6 (sCD44v6) was also higher in the same patients (287±121 vs. 220±59, P=0.056). However, there were no correlations between the concentrations of sCD44std or sCD44v6 and clinico‐pathological parameters such as grade, stage, histological type, tumor size and growth type. The ratio of sCD44std/sCD44v6 was higher in the rapid growth‐type cancers than in the slow growth‐type cancers (3.95±2.12 vs. 2.63±0.82, P=0.014). These findings suggested that the serum concentration of unknown soluble CD44 isoforms not sharing exon v6, which are present in sCD44std, increases in patients with rapid growth‐type cancers. These findings indicated that sCD44std and sCD44v6 are not useful indicators of tumor burden and metastasis in patients with renal cancer, but that an unknown sCD44 isoform(s) plays a role in the biological behavior of the rapid growth‐type cancers. |
| doi_str_mv | 10.1111/j.1349-7006.1996.tb03131.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5921015</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78693967</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6291-f94565b793dac35edd911ce5cbb4729878ab27f4c0a787fe4bf1d324928550813</originalsourceid><addsrcrecordid>eNqVkU1v1DAQhi0EKtvCT0CKAPWW4PFHHHMAVWGhlSoh0fZsOY5TvPLGrb0p7b_H0UYr4IYvPrzPjGbmQegt4Ary-7CpgDJZCozrCqSsq12HKVCoHp-h1SF6jlZYAi455vglOk5pgzEIXJMjdCQx45LjFaqvbAw-3DqjfbF-0H7SOxfGIgzFVfBT523RfmGscGPxw46ZafVobHyFXgzaJ_t6-U_Qzdf1dXteXn7_dtGeXZamJhLKQTJe805I2mtDue17CWAsN13HBJGNaHRHxMAM1qIRg2XdAD0lTJKGc9wAPUGf9n3vpm5re2PHXdRe3UW31fFJBe3U38nofqrb8KC4JICB5wanS4MY7iebdmrrkrHe69GGKSnR1JLKWmTw3T_gJkwxb5wUYflwjBBJMvVxT5kYUop2OIwCWM1u1EbNAtQsQM1u1OJGPebiN38ucyhdZOT8_ZLrlHUMMZ_apQNGeANEzpN-3mO_nLdP_zGAas_WABLobwjAqbY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2400142292</pqid></control><display><type>article</type><title>Serological Evaluation of Soluble CD44 in Renal Cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><source>IngentaConnect Free/Open Access Journals</source><source>PubMed Central</source><creator>Kan, Masaharu ; Kanayama, Hiro‐omi ; Naruo, Seiichi ; Tsuji, Masahito ; Kojima, Keiji ; Kurokawa, Yasushi ; Kagawa, Susumu</creator><creatorcontrib>Kan, Masaharu ; Kanayama, Hiro‐omi ; Naruo, Seiichi ; Tsuji, Masahito ; Kojima, Keiji ; Kurokawa, Yasushi ; Kagawa, Susumu</creatorcontrib><description>In this study, we examined the feasibility of using elevated serum CD44 concentration as an indicator in renal cancer. We performed enzyme‐linked immunosorbent assays using 63 sera obtained from 47 patients with renal cancer and 16 healthy controls and evaluated the clinico‐pathological parameters. The concentration of soluble CD44 standard (sCD44std), indicating the concentration of all circulating CD44 isoforms, was significantly higher in renal cancer patients than in normal individuals (745±170 ng/ml vs. 563±159 ng/ml, P=0.001). The concentration of soluble CD44 splice isoforms sharing exon v6 (sCD44v6) was also higher in the same patients (287±121 vs. 220±59, P=0.056). However, there were no correlations between the concentrations of sCD44std or sCD44v6 and clinico‐pathological parameters such as grade, stage, histological type, tumor size and growth type. The ratio of sCD44std/sCD44v6 was higher in the rapid growth‐type cancers than in the slow growth‐type cancers (3.95±2.12 vs. 2.63±0.82, P=0.014). These findings suggested that the serum concentration of unknown soluble CD44 isoforms not sharing exon v6, which are present in sCD44std, increases in patients with rapid growth‐type cancers. These findings indicated that sCD44std and sCD44v6 are not useful indicators of tumor burden and metastasis in patients with renal cancer, but that an unknown sCD44 isoform(s) plays a role in the biological behavior of the rapid growth‐type cancers.</description><identifier>ISSN: 0910-5050</identifier><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>EISSN: 1876-4673</identifier><identifier>DOI: 10.1111/j.1349-7006.1996.tb03131.x</identifier><identifier>PMID: 9045950</identifier><identifier>CODEN: GANNA2</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Cancer ; Carcinoma, Renal Cell - blood ; Carcinoma, Renal Cell - genetics ; CD44 antigen ; Enzyme-Linked Immunosorbent Assay ; Evaluation Studies as Topic ; Exons ; Feasibility studies ; Female ; Humans ; Hyaluronan Receptors - blood ; Hyaluronan Receptors - genetics ; Isoforms ; Isomerism ; Kidney cancer ; Kidney Neoplasms - blood ; Kidney Neoplasms - genetics ; Kidneys ; Male ; Medical sciences ; Metastases ; Middle Aged ; Nephrology. Urinary tract diseases ; Renal cancer ; Solubility ; Soluble CD44 ; Tumors of the urinary system</subject><ispartof>Cancer science, 1996-11, Vol.87 (11), p.1191-1194</ispartof><rights>1997 INIST-CNRS</rights><rights>Copyright John Wiley & Sons, Inc. Nov 1996</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6291-f94565b793dac35edd911ce5cbb4729878ab27f4c0a787fe4bf1d324928550813</citedby><cites>FETCH-LOGICAL-c6291-f94565b793dac35edd911ce5cbb4729878ab27f4c0a787fe4bf1d324928550813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921015/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921015/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,1418,27929,27930,45579,45580,53796,53798</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2581297$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9045950$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kan, Masaharu</creatorcontrib><creatorcontrib>Kanayama, Hiro‐omi</creatorcontrib><creatorcontrib>Naruo, Seiichi</creatorcontrib><creatorcontrib>Tsuji, Masahito</creatorcontrib><creatorcontrib>Kojima, Keiji</creatorcontrib><creatorcontrib>Kurokawa, Yasushi</creatorcontrib><creatorcontrib>Kagawa, Susumu</creatorcontrib><title>Serological Evaluation of Soluble CD44 in Renal Cancer</title><title>Cancer science</title><addtitle>Jpn J Cancer Res</addtitle><description>In this study, we examined the feasibility of using elevated serum CD44 concentration as an indicator in renal cancer. We performed enzyme‐linked immunosorbent assays using 63 sera obtained from 47 patients with renal cancer and 16 healthy controls and evaluated the clinico‐pathological parameters. The concentration of soluble CD44 standard (sCD44std), indicating the concentration of all circulating CD44 isoforms, was significantly higher in renal cancer patients than in normal individuals (745±170 ng/ml vs. 563±159 ng/ml, P=0.001). The concentration of soluble CD44 splice isoforms sharing exon v6 (sCD44v6) was also higher in the same patients (287±121 vs. 220±59, P=0.056). However, there were no correlations between the concentrations of sCD44std or sCD44v6 and clinico‐pathological parameters such as grade, stage, histological type, tumor size and growth type. The ratio of sCD44std/sCD44v6 was higher in the rapid growth‐type cancers than in the slow growth‐type cancers (3.95±2.12 vs. 2.63±0.82, P=0.014). These findings suggested that the serum concentration of unknown soluble CD44 isoforms not sharing exon v6, which are present in sCD44std, increases in patients with rapid growth‐type cancers. These findings indicated that sCD44std and sCD44v6 are not useful indicators of tumor burden and metastasis in patients with renal cancer, but that an unknown sCD44 isoform(s) plays a role in the biological behavior of the rapid growth‐type cancers.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cancer</subject><subject>Carcinoma, Renal Cell - blood</subject><subject>Carcinoma, Renal Cell - genetics</subject><subject>CD44 antigen</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Evaluation Studies as Topic</subject><subject>Exons</subject><subject>Feasibility studies</subject><subject>Female</subject><subject>Humans</subject><subject>Hyaluronan Receptors - blood</subject><subject>Hyaluronan Receptors - genetics</subject><subject>Isoforms</subject><subject>Isomerism</subject><subject>Kidney cancer</subject><subject>Kidney Neoplasms - blood</subject><subject>Kidney Neoplasms - genetics</subject><subject>Kidneys</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Renal cancer</subject><subject>Solubility</subject><subject>Soluble CD44</subject><subject>Tumors of the urinary system</subject><issn>0910-5050</issn><issn>1347-9032</issn><issn>1349-7006</issn><issn>1876-4673</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkU1v1DAQhi0EKtvCT0CKAPWW4PFHHHMAVWGhlSoh0fZsOY5TvPLGrb0p7b_H0UYr4IYvPrzPjGbmQegt4Ary-7CpgDJZCozrCqSsq12HKVCoHp-h1SF6jlZYAi455vglOk5pgzEIXJMjdCQx45LjFaqvbAw-3DqjfbF-0H7SOxfGIgzFVfBT523RfmGscGPxw46ZafVobHyFXgzaJ_t6-U_Qzdf1dXteXn7_dtGeXZamJhLKQTJe805I2mtDue17CWAsN13HBJGNaHRHxMAM1qIRg2XdAD0lTJKGc9wAPUGf9n3vpm5re2PHXdRe3UW31fFJBe3U38nofqrb8KC4JICB5wanS4MY7iebdmrrkrHe69GGKSnR1JLKWmTw3T_gJkwxb5wUYflwjBBJMvVxT5kYUop2OIwCWM1u1EbNAtQsQM1u1OJGPebiN38ucyhdZOT8_ZLrlHUMMZ_apQNGeANEzpN-3mO_nLdP_zGAas_WABLobwjAqbY</recordid><startdate>199611</startdate><enddate>199611</enddate><creator>Kan, Masaharu</creator><creator>Kanayama, Hiro‐omi</creator><creator>Naruo, Seiichi</creator><creator>Tsuji, Masahito</creator><creator>Kojima, Keiji</creator><creator>Kurokawa, Yasushi</creator><creator>Kagawa, Susumu</creator><general>Blackwell Publishing Ltd</general><general>Japanese Cancer Association</general><general>John Wiley & Sons, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>199611</creationdate><title>Serological Evaluation of Soluble CD44 in Renal Cancer</title><author>Kan, Masaharu ; Kanayama, Hiro‐omi ; Naruo, Seiichi ; Tsuji, Masahito ; Kojima, Keiji ; Kurokawa, Yasushi ; Kagawa, Susumu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6291-f94565b793dac35edd911ce5cbb4729878ab27f4c0a787fe4bf1d324928550813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cancer</topic><topic>Carcinoma, Renal Cell - blood</topic><topic>Carcinoma, Renal Cell - genetics</topic><topic>CD44 antigen</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Evaluation Studies as Topic</topic><topic>Exons</topic><topic>Feasibility studies</topic><topic>Female</topic><topic>Humans</topic><topic>Hyaluronan Receptors - blood</topic><topic>Hyaluronan Receptors - genetics</topic><topic>Isoforms</topic><topic>Isomerism</topic><topic>Kidney cancer</topic><topic>Kidney Neoplasms - blood</topic><topic>Kidney Neoplasms - genetics</topic><topic>Kidneys</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Renal cancer</topic><topic>Solubility</topic><topic>Soluble CD44</topic><topic>Tumors of the urinary system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kan, Masaharu</creatorcontrib><creatorcontrib>Kanayama, Hiro‐omi</creatorcontrib><creatorcontrib>Naruo, Seiichi</creatorcontrib><creatorcontrib>Tsuji, Masahito</creatorcontrib><creatorcontrib>Kojima, Keiji</creatorcontrib><creatorcontrib>Kurokawa, Yasushi</creatorcontrib><creatorcontrib>Kagawa, Susumu</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kan, Masaharu</au><au>Kanayama, Hiro‐omi</au><au>Naruo, Seiichi</au><au>Tsuji, Masahito</au><au>Kojima, Keiji</au><au>Kurokawa, Yasushi</au><au>Kagawa, Susumu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serological Evaluation of Soluble CD44 in Renal Cancer</atitle><jtitle>Cancer science</jtitle><addtitle>Jpn J Cancer Res</addtitle><date>1996-11</date><risdate>1996</risdate><volume>87</volume><issue>11</issue><spage>1191</spage><epage>1194</epage><pages>1191-1194</pages><issn>0910-5050</issn><issn>1347-9032</issn><eissn>1349-7006</eissn><eissn>1876-4673</eissn><coden>GANNA2</coden><abstract>In this study, we examined the feasibility of using elevated serum CD44 concentration as an indicator in renal cancer. We performed enzyme‐linked immunosorbent assays using 63 sera obtained from 47 patients with renal cancer and 16 healthy controls and evaluated the clinico‐pathological parameters. The concentration of soluble CD44 standard (sCD44std), indicating the concentration of all circulating CD44 isoforms, was significantly higher in renal cancer patients than in normal individuals (745±170 ng/ml vs. 563±159 ng/ml, P=0.001). The concentration of soluble CD44 splice isoforms sharing exon v6 (sCD44v6) was also higher in the same patients (287±121 vs. 220±59, P=0.056). However, there were no correlations between the concentrations of sCD44std or sCD44v6 and clinico‐pathological parameters such as grade, stage, histological type, tumor size and growth type. The ratio of sCD44std/sCD44v6 was higher in the rapid growth‐type cancers than in the slow growth‐type cancers (3.95±2.12 vs. 2.63±0.82, P=0.014). These findings suggested that the serum concentration of unknown soluble CD44 isoforms not sharing exon v6, which are present in sCD44std, increases in patients with rapid growth‐type cancers. These findings indicated that sCD44std and sCD44v6 are not useful indicators of tumor burden and metastasis in patients with renal cancer, but that an unknown sCD44 isoform(s) plays a role in the biological behavior of the rapid growth‐type cancers.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>9045950</pmid><doi>10.1111/j.1349-7006.1996.tb03131.x</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0910-5050 |
| ispartof | Cancer science, 1996-11, Vol.87 (11), p.1191-1194 |
| issn | 0910-5050 1347-9032 1349-7006 1876-4673 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5921015 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library; IngentaConnect Free/Open Access Journals; PubMed Central |
| subjects | Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Cancer Carcinoma, Renal Cell - blood Carcinoma, Renal Cell - genetics CD44 antigen Enzyme-Linked Immunosorbent Assay Evaluation Studies as Topic Exons Feasibility studies Female Humans Hyaluronan Receptors - blood Hyaluronan Receptors - genetics Isoforms Isomerism Kidney cancer Kidney Neoplasms - blood Kidney Neoplasms - genetics Kidneys Male Medical sciences Metastases Middle Aged Nephrology. Urinary tract diseases Renal cancer Solubility Soluble CD44 Tumors of the urinary system |
| title | Serological Evaluation of Soluble CD44 in Renal Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T00%3A07%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serological%20Evaluation%20of%20Soluble%20CD44%20in%20Renal%20Cancer&rft.jtitle=Cancer%20science&rft.au=Kan,%20Masaharu&rft.date=1996-11&rft.volume=87&rft.issue=11&rft.spage=1191&rft.epage=1194&rft.pages=1191-1194&rft.issn=0910-5050&rft.eissn=1349-7006&rft.coden=GANNA2&rft_id=info:doi/10.1111/j.1349-7006.1996.tb03131.x&rft_dat=%3Cproquest_pubme%3E78693967%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2400142292&rft_id=info:pmid/9045950&rfr_iscdi=true |